Disease relevance of SCG3

• GH adenomas, which are examples of well differentiated tumors based on morphological examination, expressed significantly more SgIII mRNA compared to the null cell adenomas and oncocytoma (70 +/- 6% vs. 22 +/- 5%; P < 0.001) [1].
• Genetic variations in the SCG3 gene may influence the risk of obesity through possible regulation of hypothalamic neuropeptide secretion [2].

High impact information on SCG3

• We found that CgA bound to secretogranin III (SgIII) by specific interaction both in vitro and in endocrine cells [3].
• Identification of a chromogranin A domain that mediates binding to secretogranin III and targeting to secretory granules in pituitary cells and pancreatic beta-cells [3].
• Localization analysis showed that CgA and SgIII were coexpressed in pituitary and pancreatic endocrine cell lines, whereas SgIII was not expressed in the adrenal glands and PC12 cells [3].
• NE cells expressed the regulated secretory pathway marker secretogranin III but were negative for androgen receptor and Bcl-2 [4].

Biological context of SCG3

• SgIII may take effect in the biogenesis of secretory granules as a helper protein and be involved in the production or release of peptide hormones in the regulated secretory pathway [5].

Other interactions of SCG3

• Immunoelectron microscopy demonstrated that CgA and SgIII were specifically colocalized in large secretory granules in male rat gonadotropes, which possess large-type and small-type granules [3].

Analytical, diagnostic and therapeutic context of SCG3

• Site-directed mutagenesis revealed that Xenopus SgIII is cleaved at two dibasic sites, namely Lys68-Arg69 and Arg237-Arg238 [6].
• Human SgIII is expressed widely as showed in Northern blot and its cDNA hybridizes to 2.2 kb and 1.9 kb bands in many tissues, with two additional 4.5 kb and 3.3 kb bands in brain [5].
• Subcelluar localization and immunoblotting indicated SgIII was secreted out of cell through trans-Golgi network (TGN) [5].

References